Clinical trial · Interventional
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. AE-941 may help shrink or slow the growth of non-small cell lung cancer cells. It is not yet known if combination chemotherapy plus radiation therapy is more effective with or without AE-941 for non-small cell lung cancer. This randomized phase III trial is studying combination chemotherapy and radiation therapy given with AE-941 to see how well they work compared to combination chemotherapy and radiation therapy alone in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of the Lung | Lung Adenocarcinoma | ALIAS | 0.90 |
| Adenosquamous Cell Lung Cancer | — | UNRESOLVED | — |
| Large Cell Lung Cancer | Lung Large Cell Carcinoma | ALIAS | 0.90 |
| Squamous Cell Lung Cancer | Lung Squamous Cell Carcinoma | ALIAS | 0.90 |
| Stage IIIA Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
| Stage IIIB Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin | Drug | Carboplatin | ALIAS |
| cisplatin | Drug | Cisplatin | ALIAS |
| paclitaxel | Drug | Paclitaxel | ALIAS |
| placebo | Other | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
| shark cartilage extract AE-941 | Drug | — | UNRESOLVED |
| vinorelbine tartrate | Drug | Vinorelbine | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm I (shark cartilage extract AE-941)
- description
- Patients receive oral AE-941 (Neovastat) twice daily beginning on day 1 or within 10 days of initiation of chemotherapy. All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85. All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity.
- interventionNames
- Drug: shark cartilage extract AE-941
- Drug: cisplatin
- Drug: vinorelbine tartrate
- Drug: carboplatin
- Drug: paclitaxel
- Radiation: radiation therapy
- type
- PLACEBO_COMPARATOR
- label
- Arm II (placebo)
- description
- Patients receive oral placebo twice daily beginning on day 1 or within 10 days of initiation of chemotherapy. All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85. All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed newly diagnosed, untreated, unresectable stage IIIA or stage IIIB non-small cell lung cancer * Squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung * Mixed tumors allowed if non-small cell elements identified * Contralateral supraclavicular and/or scalene lymph node involvement allowed * No disease extending into the cervical region * At least 1 bidimensionally or unidimensionally measurable lesion * No pleural effusion unless cytologically negative or too small to safely aspirate * Not scheduled for curative cancer surgery * Performance status - ECOG 0-1 * Absolute neutrophil count greater than 1,500/mm\^3 * Platelet count greater than 100,000/mm\^3 * Hematocrit greater than 30% * SGOT or SGPT less than 1.5 times upper limit of normal * Bilirubin normal * Creatinine less than 1.5 mg/dL * Creatinine clearance greater than 60 mL/min * No other major medical or psychiatric illness that would preclude study participation or consent * No medical condition that interferes with oral medication intake and/or absorption (gastrectomy or major intestinal resection) * No grade 2 or greater peripheral neuropathy unless secondary to mechanical etiology * No hypersensitivity to fish products * No more than 10% weight loss within past 3 months * No other malignancy within past 3 years except inactive carcinoma in situ of the cervix or nonmelanoma skin cancer * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * At least 30 days since prior chemotherapy * See Disease Characteristics * Recovered from prior major surgery * At least 30 days since prior shark cartilage products * No other concurrent investigational anticancer agents * No other concurrent cartilage products * No other concurrent investigational agents * No concurrent amifostine or other radioprotectants * No concurrent enrollment in other clinical trials
References
Publications (0)
Data not yet available